Cited by 56Nanoparticle-Based Drug DeliveryRNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Liposomes with cyclic RGD peptide motif triggers acute immune response in mice

Wang, Xiaoyi, Wang, Huan, Jiang, Kuan, Zhang, Yanyu, Zhan, Changyou, Ying, Man, Zhang, Mingfei, Lu, Linwei +5 more·2019·Journal of Controlled Release

Abstract

Liposomes with peptides motifs have been widely applied for targeted delivery of anticancer drugs. However, few studies have questioned whether peptide modification on liposomes may induce serious toxicity associated with immune stimulation. Here, we report that display of a tumor targeting cyclic RGD peptide (e.g. c(RGDyK) and c(RGDfK) on the surface of liposomes can be a potent inducer of lethal hypersensitivity-like reactions in mice upon re-administration, with the main symptom a sudden drop in body temperature. The hypothermia usually abates within 4 h but is sometimes lethal with death happening within 30 min post injection. This reaction has been proven to be IgE-independent acute systemic anaphylaxis, which may due to IgG immune complex triggered complement activation, anaphylatoxin and cytokine release, etc., leading to acute conspicuous organ damage. Results from an exploration of influence factors showed that the immunotoxicity of c(RGDyK)-liposomes could not be eliminated by minimizing the c(RGDyK) motif ratio, or by decreasing injection doses in the normal dose range, or by increasing the mPEG-DSPE motif ratio. However, encapsulation of a strong cytotoxic drug completely shut off this unwanted immune response. Investigation with a series of peptides containing the RGD sequence suggested that the lethal immunotoxicity of the cyclic RGD peptide was RGD sequence and peptide cyclization dependent. This study provides a valuable alert for the utilization of peptide modified liposomes in drug delivery, especially when carrying low-toxicity drugs.

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2018.12.003

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • RGD-based peptide delivery system may be allied with severe immune activation.

    “However, the RGD-based peptide delivery system may be allied with severe immune activation [48].”
  • Precise regulation over ECM-targeted peptide-based nanoparticles reduces immunotoxicity and side effects and enhances drug delivery in addition to EPR and therapeutic effects.

    “This study indicated that precise regulation over ECM-targeted peptide-based NPs reduces immunotoxicity, and its side effects, and enhances drug delivery in addition to EPR, as well as the therapeutic effects [48].”
  • Encapsulation of doxorubicin into RGD-based nanodrugs targeting ECM reduces immunotoxicity and lethal IgG response in patients.

    “For example, encapsulation of the cytotoxic drug doxorubicin into RGD-based nanodrugs targeting ECM knocks off fatal reactions and immunotoxicity, inhibiting the inadvertent lethal IgG response in patients.”

The citation lists haven’t been fetched yet

References 71 · Cited by 56

Authors
Wang, X., Wang, H., Jiang, K., Zhang, Y., Zhan, C., Ying, M., Zhang, M., Lu, L., Wang, R., Wang, S., Burgess, D. J., Wang, H., & Lu, W.
Affiliations
  • Fudan University (CN)
  • Shanghai Medical College of Fudan University (CN)
  • University of Connecticut (US)
Corresponding author
  • Wang, Hao
  • Lu, Weiyue
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2019-01
Volume
293
Pages
201-214
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2901991679
Cited by
56
References
71
Citations by year
2026: 3 · 2025: 13 · 2024: 7 · 2023: 6 · 2022: 5 · 2021: 5 · 2020: 12 · 2019: 5
FWCI
1.78
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Controlled Release (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81773657, 81690263, 81473149)
  • Shanghai Education Commission Major Project (2017-01-07-00-07-E00052)
  • Shanghai International Science and Technology Cooperation Project (16430723800)
  • National Basic Research Program of China (2013CB932500)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
cyclic RGD peptide, liposomes, immunotoxicity, systemic anaphylaxis, IgG immune complexes, complement activation, anaphylatoxins, cytokine production, tumor targeting, drug encapsulation, peptide cyclization, targeted drug delivery
MeSH terms
Anaphylaxis, Animals, Complement Activation, Hypothermia, Immunoglobulins, Liposomes, Lymphocytes, Mice, Inbred BALB C, Mice, Inbred ICR, Oligopeptides, Cytokines, Integrin alphaVbeta3, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review